Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) will report its second-quarter 2026 financial results on July 30 before U.S. markets open, giving investors an updated view of the commercial performance …
Madrigal Pharmaceuticals Sets July 30 Earnings Release as Investors Await MASH Update Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) has secured three new U.S. patents for its liver disease drug Rezdiffra, extending intellectual property protection for key treatment methods through as …
Madrigal Expands Rezdiffra Patent Portfolio Into 2045 Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) granted equity awards to seven newly hired non-executive employees under its inducement plan, using stock-based compensation to support recruitment as the biotechnology company …
Madrigal Grants Equity Awards to Seven New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) recently granted equity awards to five newly hired employees under its inducement plan, continuing the use of stock-based compensation to attract talent …
Madrigal Grants Equity Awards to Five New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) granted equity awards to 20 newly hired employees under its inducement compensation plan, a move tied to ongoing workforce expansion as the company …
Madrigal Grants Equity Awards to 20 New Employees Under Inducement Plan Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is set to present at the Goldman Sachs Global Healthcare Conference this week as investors evaluate the commercial trajectory of Rezdiffra, the …
Madrigal Investors Focus on Rezdiffra Growth at Goldman Event Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) reported new clinical and real-world data suggesting its liver disease drug Rezdiffra may reduce both cardiovascular and liver-related risk markers in patients with …
Madrigal Highlights Rezdiffra Data as MASH Market Expands Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) granted equity awards to 15 newly hired employees as the biotechnology company continues expanding operations around its approved liver disease treatment Rezdiffra and …
Madrigal Expands Workforce With Equity Hiring Grants Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) granted equity inducement awards to 47 newly hired non-executive employees as the company expands operations following the commercial launch of its MASH treatment …
Madrigal Pharmaceuticals Issues Equity Awards to 47 New Hires Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) reported first-quarter Rezdiffra sales of $311.3 million, more than doubling from a year earlier as physician adoption accelerated for the company’s liver …
Madrigal Rezdiffra Sales More Than Double in First Quarter Read More